A pharmacokinetics study of edoxaban in non-small cell lung cancer patients harboring EGFR mutation combined with venous thromboembolism
Latest Information Update: 30 Sep 2019
Price :
$35 *
At a glance
- Drugs Edoxaban (Primary)
- Indications Venous thromboembolism
- Focus Pharmacokinetics
- 28 Sep 2019 Status changed from recruiting to completed.
- 19 Jun 2016 Status changed from not yet recruiting to recruiting.
- 30 May 2016 New trial record